102 related articles for article (PubMed ID: 28045167)
1. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma.
Bhunia S; Radha V; Chaudhuri A
Nanoscale; 2017 Jan; 9(3):1201-1212. PubMed ID: 28045167
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
[TBL] [Abstract][Full Text] [Related]
3. Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes.
Hemati M; Haghiralsadat F; Jafary F; Moosavizadeh S; Moradi A
Int J Nanomedicine; 2019; 14():6575-6585. PubMed ID: 31616144
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes.
Guan J; Sun J; Sun F; Lou B; Zhang D; Mashayekhi V; Sadeghi N; Storm G; Mastrobattista E; He Z
Nanoscale; 2017 Jul; 9(26):9190-9201. PubMed ID: 28650490
[TBL] [Abstract][Full Text] [Related]
5. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
6. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
8. Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma.
Sun X; Chen Y; Zhao H; Qiao G; Liu M; Zhang C; Cui D; Ma L
Drug Deliv; 2018 Nov; 25(1):1718-1727. PubMed ID: 30269613
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of cell penetrating peptide TAT and cleavable PEGco-modified liposomes loaded with paclitaxel and its in vitro apoptosis assay].
Fu H; Hu GL; He Q
Yao Xue Xue Bao; 2014 Jul; 49(7):1054-61. PubMed ID: 25233640
[TBL] [Abstract][Full Text] [Related]
10. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Bhunia S; Vangala V; Bhattacharya D; Ravuri HG; Kuncha M; Chakravarty S; Sistla R; Chaudhuri A
Mol Pharm; 2017 Nov; 14(11):3834-3847. PubMed ID: 28958145
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted paclitaxel-loaded folate conjugated poly(ethylene glycol)-poly(L-lactide) microparticles produced by supercritical fluid technology.
Huang X; Zhang Y; Yin G; Pu X; Liao X; Huang Z; Chen X; Yao Y
J Mater Sci Mater Med; 2015 Feb; 26(2):95. PubMed ID: 25649516
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes.
Monpara J; Kanthou C; Tozer GM; Vavia PR
Pharm Res; 2018 Mar; 35(4):90. PubMed ID: 29520495
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
15. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK
Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492
[TBL] [Abstract][Full Text] [Related]
16. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
17. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
18. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
